## GARDP PIPELINE

### PROGRAMMES

#### SERIOUS BACTERIAL INFECTIONS

- HIPS library screening
- CALIBR ReFRAME library screening
- Japanese Consortium library screening: Eisai, Takeda & Daiichi Sankyo

#### NEONATAL SEPSIS

- Fosfomycin
- Flomoxef
- Amikacin
- Polymyxin B
- Pediatric cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals
- Potential candidate A (NCE or repurposed)

#### PAEDIATRIC

- Sitaflloxacin
- Potential candidate B (NCE)
- Potential candidate C (NCE)

#### SEXUALLY TRANSMITTED INFECTIONS

- Amikacin
- Polymyxin B
- Zoliflodacin (NCE) Entasis Therapeutics Inc.

### DISCOVERY

- Pre-clinical
- Phase 1
- Phase 2a PoC

### TRANSLATIONAL

- Phase 2b/3
- Registration
- Access-Stewardship

### DEVELOPMENT

- Cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals
- Treatment regimen neonatal sepsis
- Treatment options serious bacterial infections paediatric and neonates
- Zoliflodacin (NCE) Entasis Therapeutics Inc.
- Approved in EU, with limited Neo & Paeds label
- Approved in Asia: Neo & Paeds data
- Approved globally: Neo & Paeds data
- Approved in USA, with limited Neo & Paeds label
- Access strategy Including manufacturing development

### IMPLEMENTATION

1 Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Wellcome Trust in the United Kingdom

April 2020